INNOVIVA, INC. Income (Loss) from Equity Method Investments
INNOVIVA, INC. (INVA) reported Income (Loss) from Equity Method Investments of -$131.83 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2026-08-05
- INNOVIVA, INC. income (loss) from equity method investments for the quarter ending 2026-06-30 was -$131.83M, a 1107.75% decline year-over-year.
- INNOVIVA, INC. income (loss) from equity method investments for the quarter ending 2026-03-31 was $157.65M.
- INNOVIVA, INC. income (loss) from equity method investments for the quarter ending 2025-12-31 was $111.15M.
- INNOVIVA, INC. income (loss) from equity method investments for the quarter ending 2025-09-30 was $30.75M.
- INNOVIVA, INC. income (loss) from equity method investments for fiscal 2025 was $141.43M.
- INNOVIVA, INC. income (loss) from equity method investments for fiscal 2024 was -$64.25M, a 183.02% decline from fiscal 2023.
- INNOVIVA, INC. income (loss) from equity method investments for fiscal 2023 was $77.39M.
- INNOVIVA, INC. income (loss) from equity method investments for fiscal 2022 was -$161.75M, a 291.66% decline from fiscal 2021.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$131.83M 10-Q · filed 2026-08-05 | $25.82M 10-Q · filed 2026-08-05 | $136.97M derived: sum of 3 quarters · filed 2026-08-05 | $167.72M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $157.65M 10-Q · filed 2026-05-06 | $268.80M derived: sum of 2 quarters · filed 2026-05-06 | $299.55M derived: sum of 3 quarters · filed 2026-05-06 | $312.63M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $111.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $141.90M derived: sum of 2 quarters · filed 2026-02-25 | $154.98M derived: sum of 3 quarters · filed 2026-08-05 | $141.43M 10-K · filed 2026-02-25 |
| 2025-09-30 | $30.75M 10-Q · filed 2025-11-05 | $43.83M derived: sum of 2 quarters · filed 2026-08-05 | $30.28M 10-Q · filed 2025-11-05 | $9.03M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $13.08M 10-Q · filed 2026-08-05 | -$467.00K 10-Q · filed 2026-08-05 | -$21.72M derived: sum of 3 quarters · filed 2026-08-05 | -$39.95M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$13.55M 10-Q · filed 2026-05-06 | -$34.80M derived: sum of 2 quarters · filed 2026-05-06 | -$53.04M derived: sum of 3 quarters · filed 2026-05-06 | -$113.14M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$21.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$39.49M derived: sum of 2 quarters · filed 2026-02-25 | -$99.59M derived: sum of 3 quarters · filed 2026-02-25 | -$64.25M 10-K · filed 2026-02-25 |
| 2024-09-30 | -$18.23M 10-Q · filed 2025-11-05 | -$78.34M derived: sum of 2 quarters · filed 2025-11-05 | -$43.00M 10-Q · filed 2025-11-05 | -$33.49M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | -$60.11M 10-Q · filed 2025-08-06 | -$24.77M 10-Q · filed 2025-08-06 | -$15.26M derived: sum of 3 quarters · filed 2026-02-25 | $56.72M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $35.34M 10-Q · filed 2025-05-07 | $44.85M derived: sum of 2 quarters · filed 2026-02-25 | $116.83M derived: sum of 3 quarters · filed 2026-02-25 | $96.92M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $9.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $81.49M derived: sum of 2 quarters · filed 2026-02-25 | $61.58M derived: sum of 3 quarters · filed 2026-02-25 | $77.39M 10-K · filed 2026-02-25 |
| 2023-09-30 | $71.98M 10-Q · filed 2024-11-06 | $52.07M derived: sum of 2 quarters · filed 2024-11-06 | $67.89M 10-Q · filed 2024-11-06 | -$49.39M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | -$19.91M 10-Q · filed 2024-07-31 | -$4.09M 10-Q · filed 2024-07-31 | -$121.37M derived: sum of 3 quarters · filed 2025-02-26 | -$111.07M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $15.82M 10-Q · filed 2024-05-08 | -$101.46M derived: sum of 2 quarters · filed 2025-02-26 | -$91.16M derived: sum of 3 quarters · filed 2025-02-26 | -$133.98M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | -$117.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$106.98M derived: sum of 2 quarters · filed 2025-02-26 | -$149.80M derived: sum of 3 quarters · filed 2025-02-26 | -$161.75M 10-K · filed 2025-02-26 |
| 2022-09-30 | $10.30M 10-Q · filed 2023-11-01 | -$32.52M derived: sum of 2 quarters · filed 2023-11-01 | -$44.48M 10-Q · filed 2023-11-01 | |
| 2022-06-30 | -$42.82M 10-Q · filed 2023-08-02 | -$54.77M 10-Q · filed 2023-08-02 | ||
| 2022-03-31 | -$11.95M 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $84.39M 10-K/A · filed 2024-03-05 | |||
| 2020-12-31 | $49.51M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |